The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
7 pts

Opinion on  ViroPharma Inc (VPHM)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
ViroPharma: Cheap Cheap Cheap

Jan 18, 2008 02:08 AM GMT
Return Risk
-32.82% MID
Sr. Analyst

Fundamental Analysis  

This company has great cash flow, a great product line, very profitable and is frankly in the right spot at the right time.  A primary focus is antibiotic resistant strep (a growing concern in the US).  The company has a P/E of 7.5 which more than qualifies it as a value stock.  Recently this stock has been talked about by several small cap managers on CNBC and Bloomberg showing that it is finally starting to be noticed. 

Disclosure: I do not hold this stock personally but several of my client do.


VPHM:  This call was made on 01/18/08 @ $9.2
Rating:   Positive   $9.2 (01/18/08)
Gain/Loss:   -12.28% in 685 days
Target:   $12.00 (+30.43%) in > one year
Allocation:   1.7% of portfolio


+ Referring to this analysis:


Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

Who voted on this idea?
P1090585_5x7_ac_-_by_dan_mcafee__c__2007
Dan McAfee 13% 01/24/2008


Ratings referring to this analysis Agree     Disagree



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 21.10 +34.44% 381
2 18.14 +71.24% 211
3 17.66 +25.60% 55
4 13.47 +14.32% 62
5 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
ViroPharma Inc (VPHM)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
97.5%
Top:
100.0%




Latest Picks by Mike
Symbol SP Sentiment Rating Return Since
GE Positive -50.59% 04/13/08
CROX Positive -73.30% 03/08/08
TMR Positive -81.33% 03/08/08
TGB Positive -24.53% 03/08/08
TEX Positive -70.33% 03/08/08

View All >
   




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch